hVIVO bolsters its clinical research capabilities with the €10 million acquisition of CRS Clinical Research Services Management GmbH, expanding its reach in Europe.
hVIVO plc, a leading CRO, collaborated with Shionogi for a successful Phase 2a RSV antiviral trial. Positive results show significant reduction in viral load.
hVIVO, a leader in pharmaceutical services, recently expanded its European footprint with the acquisition of two clinical trial units in Germany.
hVIVO plc partners with Inhalon Biopharma, Inc. to test inhaled IN-002 antiviral candidate using RSV Human Challenge Model. Trial set to commence in H2 2026.
hVIVO plc has acquired two Clinical Research Units from CRS, boosting its capabilities in conducting human challenge clinical trials and expanding services.
Explore the innovative world of field studies with FluCamp, revolutionising clinical research by bringing trials closer to real-life scenarios.
hVIVO plc partners with ILiAD Biotechnologies for Phase 3 trial of Bordetella pertussis vaccine, marking a significant milestone in preventing whooping cough.
hVIVO plc achieves milestone with £3.2 million hLAB contract, showcasing growth in laboratory services. Read about the company’s latest achievement here.
hVIVO pioneers infectious disease research with successful hMPV study.
hVIVO plc, a leading CRO specializing in infectious disease testing, announces a £2.7m virology lab contract with a US biotech client.
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
